SG11202111983PA - Amorphous pi3k inhibitor and pharmaceutical composition comprising same - Google Patents
Amorphous pi3k inhibitor and pharmaceutical composition comprising sameInfo
- Publication number
- SG11202111983PA SG11202111983PA SG11202111983PA SG11202111983PA SG11202111983PA SG 11202111983P A SG11202111983P A SG 11202111983PA SG 11202111983P A SG11202111983P A SG 11202111983PA SG 11202111983P A SG11202111983P A SG 11202111983PA SG 11202111983P A SG11202111983P A SG 11202111983PA
- Authority
- SG
- Singapore
- Prior art keywords
- amorphous
- same
- pharmaceutical composition
- pi3k inhibitor
- pi3k
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190054507A KR20200129705A (en) | 2019-05-09 | 2019-05-09 | PI3K Inhibitor of Amorphous and Pharmaceutical Composition Comprising the same |
| PCT/IB2020/054365 WO2020225782A1 (en) | 2019-05-09 | 2020-05-08 | Amorphous pi3k inhibitor and pharmaceutical composition comprising same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111983PA true SG11202111983PA (en) | 2021-12-30 |
Family
ID=73050814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111983PA SG11202111983PA (en) | 2019-05-09 | 2020-05-08 | Amorphous pi3k inhibitor and pharmaceutical composition comprising same |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220227759A1 (en) |
| EP (1) | EP3967693A4 (en) |
| JP (1) | JP2022532186A (en) |
| KR (2) | KR20200129705A (en) |
| CN (1) | CN113795492A (en) |
| AU (1) | AU2020270027A1 (en) |
| BR (1) | BR112021022544A2 (en) |
| CA (1) | CA3134572A1 (en) |
| MX (1) | MX2021013647A (en) |
| SG (1) | SG11202111983PA (en) |
| WO (1) | WO2020225782A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA115767C2 (en) * | 2011-01-10 | 2017-12-26 | Інфініті Фармасьютікалз, Інк. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| AR092501A1 (en) * | 2012-09-13 | 2015-04-22 | Sanofi Sa | CRYSTAL COMPOUNDS |
| WO2015160975A2 (en) * | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| KR101845931B1 (en) * | 2015-06-18 | 2018-04-05 | 한국화학연구원 | Heteroaryl derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating PI3 kinase related diseases |
| WO2016204429A1 (en) | 2015-06-18 | 2016-12-22 | 한국화학연구원 | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient |
| AU2016322552B2 (en) * | 2015-09-14 | 2021-03-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
-
2019
- 2019-05-09 KR KR1020190054507A patent/KR20200129705A/en not_active Application Discontinuation
-
2020
- 2020-05-08 JP JP2021566580A patent/JP2022532186A/en active Pending
- 2020-05-08 CA CA3134572A patent/CA3134572A1/en active Pending
- 2020-05-08 BR BR112021022544A patent/BR112021022544A2/en unknown
- 2020-05-08 SG SG11202111983PA patent/SG11202111983PA/en unknown
- 2020-05-08 MX MX2021013647A patent/MX2021013647A/en unknown
- 2020-05-08 CN CN202080032970.3A patent/CN113795492A/en active Pending
- 2020-05-08 EP EP20802939.7A patent/EP3967693A4/en not_active Withdrawn
- 2020-05-08 US US17/609,270 patent/US20220227759A1/en active Pending
- 2020-05-08 AU AU2020270027A patent/AU2020270027A1/en not_active Withdrawn
- 2020-05-08 WO PCT/IB2020/054365 patent/WO2020225782A1/en unknown
- 2020-05-08 KR KR1020217040285A patent/KR20210155805A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020225782A1 (en) | 2020-11-12 |
| EP3967693A1 (en) | 2022-03-16 |
| KR20200129705A (en) | 2020-11-18 |
| JP2022532186A (en) | 2022-07-13 |
| CA3134572A1 (en) | 2020-11-12 |
| AU2020270027A1 (en) | 2021-11-25 |
| MX2021013647A (en) | 2022-01-06 |
| KR20210155805A (en) | 2021-12-23 |
| BR112021022544A2 (en) | 2021-12-28 |
| CN113795492A (en) | 2021-12-14 |
| EP3967693A4 (en) | 2023-01-18 |
| US20220227759A1 (en) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3806858A4 (en) | Kinase inhibitor salts and compositions thereof | |
| EP3741374A4 (en) | Mtor inhibitor, pharmaceutical composition and use thereof | |
| EP3706741A4 (en) | Pharmaceutical composition and use thereof | |
| IL286248A (en) | Tyk2 inhibitors and uses thereof | |
| IL284799A (en) | Tyk2 inhibitors and uses thereof | |
| EP2999691A4 (en) | Cryopyrin inhibitors for preventing and treating inflammation | |
| EP3681499A4 (en) | Compounds as ras inhibitors and use thereof | |
| EP3858353A4 (en) | Pharmaceutical composition for preventing and treating nitm and pharmaceutical use thereof | |
| PL4084778T3 (en) | Amorphous kinase inhibitor formulations and methods of use thereof | |
| IL291191A (en) | Cdk inhibitors and their use as pharmaceuticals | |
| IL282350A (en) | Rgmc-selective inhibitors and use thereof | |
| EP3762392A4 (en) | Thienopyridine derivatives and pharmaceutical composition comprising same | |
| EP3741758A4 (en) | Bromodomain inhibitor compound and use thereof | |
| IL284745A (en) | Gpr174 inhibitor containing compositions and uses thereof | |
| EP3712147B8 (en) | Sglts inhibitor and application thereof | |
| EP3897670A4 (en) | Inhibitors of sarm1 in combination with neuroprotective agents | |
| IL285595A (en) | Spt5 inhibitors and uses thereof | |
| EP4071155A4 (en) | Thiazololactam compound as erk inhibitor and use thereof | |
| IL282688A (en) | Cyclodextrin-based formulation of a bcl-2 inhibitor | |
| IL281357B (en) | Cd73 inhibitors and pharmaceutical uses thereof | |
| IL292198A (en) | Tim-3 inhibitors and uses thereof | |
| IL279276A (en) | Erk inhibitor and use thereof | |
| EP4063489A4 (en) | Composition and use thereof | |
| EP3630113A4 (en) | Pharmaceutical composition comprising pde9 inhibitor | |
| EP3828184A4 (en) | Pyrazolopyrimidine derivative and use thereof as pi3k inhibitor |